◀ Back to MTOR
FKBP8 — MTOR
Pathways - manually collected, often from reviews:
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Pieretti-Vanmarcke et al., Proc Natl Acad Sci U S A 2006
(Ovarian Neoplasms) :
Because MIS releases
FK506 binding protein ( FKBP12 ), which
activates the
mammalian target of rapamycin (mTOR) downstream of Akt, rhMIS and rapamycin combinations were tested
Wang et al., J Biol Chem 2008
:
Furthermore,
FKBP38 did not
inhibit mTORC1 signaling ... Our data also indicate that, in the mammalian cell lines tested here, neither TCTP nor
FKBP38 regulates
mTORC1 signaling
Uhlenbrock et al., FEBS Lett 2009
:
Cell biological experiments illustrate that
FKBP38 plays only a very minor, if any, role in
mTORC1 activation
Dunlop et al., Cell Signal 2009
:
We found that
FKBP38 inhibits
mTOR ( L1460P ), while the mTOR ( E2419K ) kinase domain mutant was resistant to FKBP38 inhibition ... Finally, we show that activation of
mTORC1 by both Rheb and RhebL1 is
impaired by
FKBP38
Peng et al., J Biol Chem 2010
:
Overexpression of NS5A and FKBP38 mutants or FKBP38 knockdown revealed this
mTOR activation was
dependent on
NS5A-FKBP38 interaction ... Additionally, NS5A or
FKBP38 mutants
recovered the
mTOR-FKBP38 interaction ; this indicated that the impairment of mTOR-FKBP38 association was dependent on NS5A-FKBP38 binding
Yoon et al., J Biol Chem 2011
:
This leads to PA antagonizing
FKBP38 inhibition of
mTORC1 kinase activity in vitro and rescuing mTORC1 signaling from FKBP38 in cells